Leukemia initiating cells (LICs) in acute myeloid leukemia (AML) are believed to be restricted to the CD34 + fraction. However, one of the most frequently mutated genes in AML is nucleophosmin (NPM) and this is associated with low CD34 expression. We therefore investigated whether NPM 
Introduction
Normal hematopoiesis is organized as a hierarchy with hematopoietic stem cells (HSCs) at the apex and differentiated blood cells at the base. Acute myeloid leukemia (AML) is thought to be organized in a similar way with leukemia initiating cells (LICs) at the top of the hierarchy giving rise to variably differentiated blasts. 1 LICs are thought to be critical to the growth of AML hence elimination of these is important to obtain a cure. To study and target LICs one must know their phenotype. Two publications suggested that they all reside within the CD34 + CD38 -fraction of AML.
1,2
We have recently shown that anti-CD38 antibody eliminates some LICs from immunodeficient mice through immune clearance. 3 When this effect of anti-CD38 antibody was abrogated we noted that the CD34 + CD38 + fraction of seven AML samples could initiate leukemia in immunodeficient mice. Moreover, we noted that some leukemias had no LICs in the CD34 + CD38 -fraction. This suggested that there is more heterogeneity in the phenotype of LICs than the original studies indicated.
Nucleophosmin (NPM) is one of the genes most commonly mutated in AML. 4 NPM is a heterozygous mutation 5 that appears to be stable over the disease course. 6, 7 AML with NPM mutation has distinct clinical, 5, 8, 9 cytogenetic, 4,10 molecular [11] [12] [13] and immunological features 4, 7, 13 that have lead to its inclusion in the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues (4 th edition) as a separate provisional entity. 14 Of note, NPM mutated AML is associated with low expression of CD34 4, 7, 13 . Although many AML samples are termed 'CD34 negative' by diagnostic laboratories, negativity is typically defined by less than 20%
For personal use only. on April 30, 2017. by guest www.bloodjournal.org From of blast cells expressing CD34. Thus many samples that are defined as 'CD34 negative' actually have a small population of CD34 positive cells and this may contain the LICs as previously reported. However, we have observed normal human hematopoietic cells in the bone marrow of mice transplanted with the CD34 + CD38 -fraction of one AML with mutated NPM suggesting that this fraction may contain normal hematopoietic progenitors in some AML specimens. 3 This led us to question whether LICs express CD34 in all NPM mutated AML specimens.
In order to investigate this, we tested CD34 + and CD34 -cells from NPM mutated AMLs using genomic and functional assays. CD34 + and CD34 -cells were transplanted into immunodeficient mice to identify which fraction contained LICs. We used the most immunodeficient mice available and employed measures to abrogate the effect of antibody mediated clearance. 3 The CD34 -cells alone initiated leukemia from approximately half of samples (that we termed subtype A) while the CD34 + cells gave rise to normal multi-lineage hematopoiesis. Most other samples had LICs within both CD34 + and CD34 -fractions, and these were capable of transmitting leukemia to secondary recipients. The data indicate that one cannot blindly rely on the CD34 + CD38 -phenotype to identify LICs from all AMLs. We also show that the phenotype of LICs can change and this provides a probable explanation for the presence of LICs in multiple fractions from some AMLs.
Methods and materials

Primary cells
Cord blood and acute myeloid leukemia (AML) cells were obtained after informed consent at St
Bartholomew's and the Royal London Hospitals. The protocol was approved by the East London and City Research Ethics Committee. The samples were collected at untreated presentation (n=26) ) was the preferred route of administration unless more than 10 6 cells were administered where the intravenous route was preferred.
Assessment of engraftment
Engraftment was assessed by immunophenotyping as described before. 
Results
Classification of AML with NPM mutation according to phenotype
Immunophenotyping was performed on twenty-seven AML samples all of which had mutated NPM ( (Tables 4 and Tables S1-2 (Table 5) . Therefore, the LICs we describe can maintain and propagate leukemia over prolonged periods and are not simply short-lived leukemic progenitors.
Frequency of LICs in each fraction
The frequency of LICs in specific fractions was determined by limiting dilution analysis of four sorted samples ( (Table S3) . Myelo-monocytic and monocytic/blastic subtypes (M4 and M5) expressed mature monocytic markers while myeloblastic subtypes (M1 and M2) expressed CD33 but only a small minority of cells expressed the mature myelo-monocytic markers ( Figure S3 ).
However we noted some changes in the phenotype of engrafted AML cells. Only one of thirteen samples (sample 19) maintained expression of CD34. The majority of engrafted leukemia cells had a CD34 -CD38 + phenotype (Figure 2 ). By contrast a CD34 + population was seen in the normal graft derived from the CD34 + CD38 -fraction of sample 15 ( Figure 2Biv ). Given that the CD34 + fraction from some subtype C samples initiated leukemia in primary and secondary recipients and yet engrafted cells did not express CD34, the data suggest that the CD34 + LICs had lost CD34 expression in the mice. Similarly, LICs from sample 7 were shown to lack CD14 expression in the primary sample but become CD14 + within the mice (Figure 3 ).
NPM wild type AMLs with low CD34 expression have CD34 -LICs
Although the expression of CD34 is significantly higher in NPM wild type AML, some NPM wild type samples have low expression of CD34. We sorted two such wild type NPM samples (termed WT1 and WT2) and transplanted the cells into immunodeficient mice. The LICs were restricted to the CD34 -fraction (Tables 3 and 4 and 9 (though sample 18 not tested).
For NT indicates not tested. *Time in vivo refers to the time from transplant of the primary recipient to the termination of the final recipient. Sample 7 is very aggressive clinically and mice became sick due to leukemia 3-5 weeks post transplant hence the relatively short duration. The expression of CD14 is seen in the primary AML sample from sample 7(A). The sample was sorted and 250,000 CD14 + cells were transplanted into three mice but no graft was detected at 9
weeks. By contrast 250,000 CD14 -cells gave rise to a graft at 9 weeks in two of two mice 
